> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-71/
- Published: 2022-03-06T12:00:00.000Z
- Updated: 2026-09-14T17:35:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151307

**Patrick Bishop Debarred for 5 Years**  
3/4/2022 *Federal Register* notice: FDA has issued an order to debar **Patrick Charles Bishop** for a period of five years from importing or offering for import any drug into the U.S. The agency based its action on Bishop’s felony conviction for importing an unapproved drug. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-03/pdf/2022-04469.pdf?ref=fdaweb.com).

**Guide on Timely Product Recalls**  
3/4/2022 *Federal Register* notice: FDA is making available a final guidance entitled “Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C.” The document provides input on timely initiation of voluntary recalls of FDA-regulated products. It also discusses preparations that firms in a distribution chain should consider making to ensure timely responses to a recall communication. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-04/pdf/2022-04704.pdf?ref=fdaweb.com).

**FDA Debars George Kuiper for 5 Years**  
3/3/2022 *Federal Register* notice: FDA is issuing an order to debar **George Kuiper** for a period of five years from importing or offering for import any drug into the U.S. The order is based on a finding that Kuiper was convicted of multiple felony offenses: One count of smuggling, one count of conspiracy to smuggle goods into the U.S. and to introduce into interstate commerce unapproved drugs, and one count of introduction into interstate commerce of unapproved drugs. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-03/pdf/2022-04484.pdf?ref=fdaweb.com)

**Info Collection Extension on Emergency Use Authorization**  
3/3/2022 *Federal Register* notice: FDA is seeking comments on an information collection extension entitled “Emergency Use Authorization of Medical Products” (OMB Control Number 0910-0595). The collection helps support implementation of agency policies applicable to authorizing medical products for use in emergencies under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-03/pdf/2022-04496.pdf?ref=fdaweb.com).

**Guide on Older Adults in Cancer Trials**  
3/2/2022 *Federal Register* notice: FDA is making available a final guidance entitled “Inclusion of Older Adults in Cancer Clinical Trials.” The document provides recommendations about including older adult patients (aged 65 and older) in oncology drug clinical trials. It also emphasizes the importance of including adults over age 75 years in cancer clinical trials. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-02/pdf/2022-04399.pdf?ref=fdaweb.com).

**Oncology Trial Master Protocols Guidance**  
3/2/2022 *Federal Register* notice: FDA is making available a final guidance entitled “Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics.” The document provides advice to sponsors about the design and conduct of clinical trials intended to simultaneously evaluate more than one investigational drug and/or more than one cancer type within the same overall trial structure (master protocols) in adult and pediatric cancers. The agency says master protocols use a single infrastructure, trial design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, allowing for efficient and accelerated drug development. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-03-02/pdf/2022-04398.pdf?ref=fdaweb.com).